Eli Lilly and Company (LLY) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Eli Lilly And Company.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.077 Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2025 earnings 00:00:05.077 -- 00:00:09.223 conference call. At this time, all participants are in a listen-only mode. 00:00:09.223 -- 00:00:13.108 Later, we will be conducting a question and answer session and instructions will be given 00:00:13.108 -- 00:00:18.234 at that time. Should you request assistance during the call, please press star, 00:00:18.234 -- 00:00:21.719 then zero, and an operator will assist you offline. 00:00:21.719 -- 00:00:26.064 I would now like to turn the conference over to your host, Mike Zappar, Senior Vice President 00:00:26.064 -- 00:00:29.747 of Investor Relations. Please go ahead. 00:00:29.967 -- 00:00:34.713 Well, good morning. Thank you for joining us for Eli Lilly and Company's Q4 2025 Earnings 00:00:34.713 -- 00:00:38.698 Call. I'm Mike Sapar, Senior Vice President of Investor Relations. 00:00:38.698 -- 00:00:43.624 Joining me on today's call are Dave Ricks, Lilly's Chair and CEO, Lucas Montarse, Chief 00:00:43.624 -- 00:00:48.711 Financial Officer, Dr. Dan Skowronski, Chief Scientific and Product Officer, 00:00:48.711 -- 00:00:51.794 Adrian Brown, President of Lilly Immunology, Dr. 00:00:51.794 -- 00:00:54.658 Carol Ho, President of Lilly Neuroscience, 00:00:54.658 -- 00:00:59.347 Olivia Ufa, President of Lilly USA and Global Customer Capabilities, Jake Van Narden, 00:00:59.347 -- 00:01:03.313 President of Biology and Head of Business Development, Patrick Janssen, President of 00:01:03.313 -- 00:01:08.460 Lilly International, and Ken Custer, President of Lilly Cardiometabolic Health. 00:01:08.460 -- 00:01:12.505 We're also joined by Mark Keeman, Susan Hedgeland, and Wes Tall of the Investor Relations 00:01:12.505 -- 00:01...